MACK — Merrimack Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $223.75m
- -$20.36m
- 42
- 37
- 78
- 51
Annual cashflow statement for Merrimack Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.3 | -3.03 | -2.46 | -1.54 | -1.18 |
| Depreciation | |||||
| Non-Cash Items | -8.1 | -0.417 | 0.253 | -0.374 | -0.277 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -8.16 | -1.18 | 1.98 | 0.176 | -0.064 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -31.4 | -4.63 | -0.218 | -1.74 | -1.52 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 69.8 | 2.14 | 0.144 | 0.445 | -12.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 69.8 | 2.14 | 0.144 | 0.445 | -12.4 |
| Financing Cash Flow Items | -0.985 | -0.056 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -42.5 | -0.056 | 0.239 | 6.53 | 0.521 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.08 | -2.54 | 0.165 | 5.24 | -13.4 |